ArticleGenes and environment : the official journal of the Japanese Environmental Mutagen Society2025
Increased mutagenicity in the liver of MutaMouse females following oral treatment with commercial-grade toluene diisocyanate.
Article in Genes and environment : the official journal of the Japanese Environmental Mutagen Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundToluene diisocyanates (TDIs) are high-production-volume chemicals widely used in polyurethane manufacturing. A typical commercial-grade TDI (TDI; 2,4-toluene diisocyanate: 2,6-toluene diisocyanate; 80:20), CAS: 26471-62-5, is mutagenic in Salmonella typhimurium with an S9 metabolic activation mix and induces chromosomal aberrations in Chinese hamster lung cells without S9 mix. While oral administration of TDI has been reported to be carcinogenic in female mice and rats of both sexes, its in vivo mutagenicity remains poorly understood. This study aimed to clarify the in vivo mutagenicity of orally administered TDI. In vivo mutagenicity was evaluated following the Organisation for Economic Co-operation and Development Test Guideline 488 (OECD TG488). MutaMouse females were orally dosed with TDI at 0 (corn oil; vehicle control), 250, 500, or 1,000 mg/kg/day for 28 days. Mutant frequencies (MFs) in the liver and glandular stomach were analyzed three days post-final dosing. Positive controls received intraperitoneal injections of N-ethyl-N-nitrosourea (ENU) at 100 mg/kg/day for two days, with MFs assessed ten days after the final dose.
resultsSignificant increases in lacZ MFs were observed in the liver at 1,000 mg/kg/day, while MFs in the glandular stomach remained unchanged. Positive controls demonstrated significantly elevated MFs in both the liver and glandular stomach.
conclusionsThese findings indicate that orally administered TDI is mutagenic in mice, supporting its classification as a mutagenic carcinogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.